Procalcitonin for the Evaluation and Antibiotic Management of Suspected Lower Respiratory Tract Infections and Sepsis

Kristian Roth, Ph.D.
Branch Chief – Bacterial Respiratory and Medical Countermeasures Branch
CDRH/OIR/DMD/BAC2

Microbiology Devices Panel Meeting
November 10, 2016
The Focus of Today’s Meeting: bioMérieux, Inc. 510(k) for Expanding the Current Intended Use for Procalcitonin
VIDAS® B•R•A•H•M•S PCT™ (PCT) is an automated test for use on the instruments of the VIDAS® family for the determination of human procalcitonin in human serum or plasma (lithium heparinate) using the ELFA (Enzyme-Linked Fluorescent Assay) technique. Used in conjunction with other laboratory findings and clinical assessments, VIDAS® B•R•A•H•M•S PCT™ is intended for use as follows:

- To aid in the risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock,
- To aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission, using a change in PCT level over time.
VIDAS® B•R•A•H•M•S PCT™ (PCT) is an automated test for use on the instruments of the VIDAS® family for the determination of human procalcitonin in human serum or plasma (lithium heparinate) using the ELFA (Enzyme-Linked Fluorescent Assay) technique. Used in conjunction with other laboratory findings and clinical assessments, VIDAS® B•R•A•H•M•S PCT™ is intended for use as follows:

- To aid in the risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock,
- To aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission, using a change in PCT level over time.

- To aid in decision making on antibiotic therapy for inpatients or outpatients, with suspected or confirmed lower respiratory tract infections (LRTI) defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD),
- To aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis.
Validation of New Claims

- Is the submitted evidence sufficient to make a determination of safety and effectiveness for the addition of these new claims:

<table>
<thead>
<tr>
<th>LRTI</th>
</tr>
</thead>
<tbody>
<tr>
<td>- As an aid in <strong>antibiotic initiation</strong> in the setting of lower respiratory tract infection;</td>
</tr>
<tr>
<td>- As an aid for antibiotic <strong>discontinuation</strong> in the setting of lower respiratory tract infection;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sepsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>- As an aid in the <strong>discontinuation</strong> of antibiotics for patients with sepsis.</td>
</tr>
</tbody>
</table>
Clinical Use of Procalcitonin

• 10+ years after the first FDA clearance for sepsis...
  – Google: ~400+K hits
  – PubMed: > 3000 citations
  – ID Week 2016: 33 Citations, special symposium

• Despite these efforts, the clinical utility of PCT remains a subject of diverging opinions

• PCT is an area of active investigation
  – e.g., ProACT and TRAP/LRTI studies
Topics for Discussion

• The current meeting reflects why opinions may be diverging and discussion is needed:
  – The expansion of the claims for PCT is significant and potentially impacts the care of numerous patients
  – Using a meta-analysis to establish new claims is atypical; is this approach sufficient to determine safety and effectiveness?
  – How much uncertainty persists following review of published studies regarding the proposed conditions of use and the proposed diagnostic algorithm?
Advisory Panel Meeting Agenda

• Presentations, comments and concerns related to the sponsor's meta-analyses of published data
• Open public comments regarding PCT-guided management
• Panel discussion of available evidence
• Panel Question: Is PCT-guided management safe and effective for the proposed use?
Agenda

8:30 a.m.  ARLG Presentation:  Dr. Ebbing Lautenbach
9:00 a.m.  bioMérieux Presentation
10:15 a.m.  Break
10:30 a.m.  FDA Presentations: Dr. Brittany Goldberg and Dr. Qin Li
11:45 a.m.  Lunch
12:45 p.m.  Open Public Hearing
1:45 p.m.  Panel Deliberations
2:45 p.m.  Break
3:00 p.m.  FDA Questions
5:00 p.m.  Chair closing remarks
5:10 p.m.  Adjournment
Thank you...

• The sponsor, bioMérieux, Inc.
• The committee and the consultants to the committee for participating in this important meeting
• And all others who have contributed...